Losartan

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 35079 Experts worldwide ranked by ideXlab platform

Richard B Devereux - One of the best experts on this subject based on the ideXlab platform.

  • Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan
    2020
    Co-Authors: Richard B Devereux, Paulette A. Lyle
    Abstract:

    Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other antihypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, Losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, Losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.

  • Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Expert Opinion on Pharmacotherapy, 2004
    Co-Authors: Richard B Devereux, Paulette A. Lyle
    Abstract:

    Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other antihypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, Losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, Losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.

  • regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol the Losartan intervention for endpoint reduction in hypertension life trial
    Circulation, 2004
    Co-Authors: Richard B Devereux, Bjorn Dahlof, Vasilios Papademetriou, Eva Gerdts, Kurt Boman, Markku S Nieminen, Jens Rokkedal, Katherine E Harris, Jonathan M Edelman, Kristian Wachtell
    Abstract:

    Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol : the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

  • does albuminuria predict cardiovascular outcome on treatment with Losartan versus atenolol in hypertension with left ventricular hypertrophy a life substudy
    Journal of Hypertension, 2004
    Co-Authors: Hans Ibsen, Richard B Devereux, Kristian Wachtell, Michael H Olsen, Knut Borchjohnsen, Lars H Lindholm, Carl Erik Mogensen, Bjorn Dahlof, Ulf De Faire, Frej Fyhrquist
    Abstract:

    ObjectivesTo examine a possible relationship between baseline albuminuria and effect of Losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of Losartan versus atenolol on albuminuria, and whether the benefits of Losartan versu

  • regression of electrocardiographic left ventricular hypertrophy by Losartan versus atenolol the Losartan intervention for endpoint reduction in hypertension life study
    Circulation, 2003
    Co-Authors: Peter M Okin, Richard B Devereux, Markku S Nieminen, Katherine E Harris, Sverre E Kjeldsen, Stevo Julius, Sverker Jern, Steven M Snapinn, Peter Aurup, Jonathan M Edelman
    Abstract:

    BACKGROUND: Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients. However, uncertainty persists as to how best to regress ECG LVH. METHODS AND RESULTS: Regression of ECG LVH with Losartan versus atenolol therapy was assessed in 9193 hypertensive patients with ECG LVH by Sokolow-Lyon voltage or Cornell voltage-duration product criteria enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Patients had ECGs at study baseline and after 6 months, 1, 2, 3, 4, and 5 years of blinded Losartan-based or atenolol-based therapy. After 6 months' follow-up, adjusting for baseline ECG LVH levels, baseline and in-treatment systolic and diastolic pressures, and for diuretic therapy, Losartan-based therapy was associated with greater regression of both Cornell product (adjusted means, -200 versus -69 mm. ms, P<0.001) and Sokolow-Lyon voltage (-2.5 versus -0.7 mm, P<0.001) than was atenolol-based therapy. Greater regression of ECG LVH persisted at each subsequent annual evaluation in the Losartan-treated group, with between 140 and 164 mm. ms greater mean reductions in Cornell product and from 1.7 to 2.2 mm greater mean reductions in Sokolow-Lyon voltage (all P<0.001). The effect of Losartan was consistent across subgroups defined by gender, age, ethnicity, and diabetes. CONCLUSIONS: After adjusting for baseline and in-treatment blood pressure and baseline severity of ECG LVH, Losartan-based antihypertensive therapy resulted in greater regression of ECG LVH by Cornell voltage-duration product and Sokolow-Lyon voltage criteria than did atenolol-based therapy. These findings support the value of angiotensin receptor blockade with Losartan for reversing ECG LVH.

Bjorn Dahlof - One of the best experts on this subject based on the ideXlab platform.

  • effect of the direct renin inhibitor aliskiren the angiotensin receptor blocker Losartan or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
    Circulation, 2009
    Co-Authors: Scott D Solomon, Evan Appelbaum, Warren J Manning, Anil Verma, Tommy Berglund, Valentina Lukashevich, Cheraz Cherif Papst, Beverly Smith, Bjorn Dahlof
    Abstract:

    Background—Left ventricular (LV) hypertrophy, a marker of cardiac end-organ damage, is associated with an increased risk of cardiovascular morbidity and mortality. Inhibitors of the renin-angiotensin-aldosterone system may reduce LV mass to a greater extent than other antihypertensive agents. We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker Losartan, and their combination on the reduction of LV mass in hypertensive patients. Methods and Results—We randomized 465 patients with hypertension, increased ventricular wall thickness, and body mass index 25 kg/m 2 to receive aliskiren 300 mg, Losartan 100 mg, or their combination daily for 9 months. Patients were treated to standard blood pressure targets with add-on therapy, excluding other inhibitors of the renin-angiotensin-aldosterone system and -blockers. Patients underwent cardiovascular magnetic resonance imaging for assessment of LV mass at baseline and at study completion. The primary objective was to compare change in LV mass index from baseline to follow-up in the combination and Losartan arms; the secondary objective was to determine whether aliskiren was noninferior to Losartan in reducing LV mass index from baseline to follow-up. Systolic and diastolic blood pressures were reduced similarly in all treatment groups (6.514.9/3.810.1 mm Hg in the aliskiren group; 5.515.6/3.710.7 mm Hg in the Losartan group; 6.616.6/4.610.5 mm Hg in the combination arm; P0.0001 within groups, P0.81 between groups). LV mass index was reduced significantly from baseline in all treatment groups (4.9-, 4.8-, and 5.8 g/m 2 reductions in the aliskiren, Losartan, and combination arms, respectively; P0.0001 for all treatment groups). The reduction in LV mass index in the combination group was not significantly different from that with Losartan alone (P0.52). Aliskiren was as effective as Losartan in reducing LV mass index (P0.0001 for noninferiority). Safety and tolerability were similar across all treatment groups. Conclusions—Aliskiren was as effective as Losartan in promoting LV mass regression. Reduction in LV mass with the combination of aliskiren plus Losartan was not significantly different from that with Losartan monotherapy, independent of blood pressure lowering. These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy. (Circulation. 2009;119:530-537.)

  • stroke reduction in hypertensive adults with cardiac hypertrophy randomized to Losartan versus atenolol the Losartan intervention for endpoint reduction in hypertension study
    Hypertension, 2005
    Co-Authors: Jorge R Kizer, Hans Ibsen, Bjorn Dahlof, Ulf De Faire, Frej Fyhrquist, Sverre E Kjeldsen, Stevo Julius, Gareth Beevers, Krister Kristianson, Ole Lederballepedersen
    Abstract:

    Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to Losartan versus atenolol : the Losartan Intervention For Endpoint reduction in hypertension study.

  • regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol the Losartan intervention for endpoint reduction in hypertension life trial
    Circulation, 2004
    Co-Authors: Richard B Devereux, Bjorn Dahlof, Vasilios Papademetriou, Eva Gerdts, Kurt Boman, Markku S Nieminen, Jens Rokkedal, Katherine E Harris, Jonathan M Edelman, Kristian Wachtell
    Abstract:

    Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol : the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

  • does albuminuria predict cardiovascular outcome on treatment with Losartan versus atenolol in hypertension with left ventricular hypertrophy a life substudy
    Journal of Hypertension, 2004
    Co-Authors: Hans Ibsen, Richard B Devereux, Kristian Wachtell, Michael H Olsen, Knut Borchjohnsen, Lars H Lindholm, Carl Erik Mogensen, Bjorn Dahlof, Ulf De Faire, Frej Fyhrquist
    Abstract:

    ObjectivesTo examine a possible relationship between baseline albuminuria and effect of Losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of Losartan versus atenolol on albuminuria, and whether the benefits of Losartan versu

Kristian Wachtell - One of the best experts on this subject based on the ideXlab platform.

Frej Fyhrquist - One of the best experts on this subject based on the ideXlab platform.

Hans Ibsen - One of the best experts on this subject based on the ideXlab platform.

Related terms

Losartan - 15 days free trial to Access Experts & Abstracts